| HUMAN-TRIAL | evidence | Gap in Sexual Dysfunction Management Between Male and Female Patients Seen in Primary Care: An Observational Study. | Bremelanotide | Sexual function & libido · human-observational | 2025-03-01 |
| HUMAN-TRIAL | evidence | Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. | Bremelanotide | Weight & fat loss · human-rct | 2022-06-01 |
| HUMAN-TRIAL | evidence | Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. | Bremelanotide | Sexual function & libido · human-rct | 2022-03-01 |
| HUMAN-TRIAL | evidence | Safety Profile of Bremelanotide Across the Clinical Development Program. | Bremelanotide | Sexual function & libido · human-rct | 2022-02-01 |
| HUMAN-TRIAL | evidence | The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results. | Bremelanotide | Sexual function & libido · human-rct | 2021-04-01 |
| HUMAN-TRIAL | evidence | Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. | Bremelanotide | Sexual function & libido · human-rct | 2019-11-01 |
| HUMAN-TRIAL | evidence | Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. | Bremelanotide | Sexual function & libido · human-rct | 2019-08-01 |
| HUMAN-TRIAL | evidence | Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. | Bremelanotide | human-rct | 2017-04-01 |
| HUMAN-TRIAL | evidence | Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. | Bremelanotide | human-rct · n = 24 | 2017-03-01 |
| HUMAN-TRIAL | evidence | Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. | Bremelanotide | Sexual function & libido · human-rct · n = 327 | 2016-06-01 |
| HUMAN-TRIAL | evidence | RETRACTED: Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. | Bremelanotide | Sexual function & libido · human-rct | 2008-04-01 |
| HUMAN-TRIAL | evidence | Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. | Bremelanotide | Sexual function & libido · human-rct · n = 342 | 2008-03-01 |
| HUMAN-TRIAL | evidence | An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. | PT 141 | Sexual function & libido · human-rct | 2006-07-01 |
| HUMAN-TRIAL | evidence | Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. | PT 141 | Sexual function & libido · human-rct | 2005-04-01 |
| HUMAN-TRIAL | evidence | Gateways to clinical trials. | PT 141 | human-observational | 2004-12-01 |
| HUMAN-TRIAL | evidence | Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. | PT 141 | Sexual function & libido · human-rct | 2004-04-01 |
| HUMAN-TRIAL | evidence | Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. | PT 141 | Sexual function & libido · human-rct | 2004-02-01 |
| HUMAN-TRIAL | evidence | PT-141: a melanocortin agonist for the treatment of sexual dysfunction. | PT 141 | Sexual function & libido · human-observational | 2003-06-01 |
| HUMAN-TRIAL | evidence | Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD) | Bremelanotide | human-rct | — |
| HUMAN-TRIAL | evidence | 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder | PT-141 | Sexual function & libido · human-rct · n = 723 | — |
| HUMAN-TRIAL | evidence | Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran | Bremelanotide | human-rct · n = 228 | — |
| HUMAN-TRIAL | evidence | Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk | Vyleesi | n = 10 | — |
| HUMAN-TRIAL | evidence | A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity | Bremelanotide | Weight & fat loss · human-rct · n = 108 | — |
| HUMAN-TRIAL | evidence | Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder | PT-141 | Sexual function & libido · human-rct · n = 612 | — |
| HUMAN-TRIAL | evidence | A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease | bremelanotide acetate | n = 16 | — |
| HUMAN-TRIAL | evidence | Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder | Bremelanotide | Sexual function & libido · human-rct · n = 40 | — |
| HUMAN-TRIAL | evidence | A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal) | Bremelanotide | Sexual function & libido · human-rct · n = 193 | — |
| HUMAN-TRIAL | evidence | 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder | PT-141 | Sexual function & libido · human-rct · n = 714 | — |
| REGULATORY | regulatory | Vyleesi — FDA prescribing information | FDA | — | 2025-11-13 |
| REGULATORY | regulatory | D-0780-2022 — PT-141 (Bremelanotide Acetate) 10 mg/mL (2 mL) Injection, 2mL vials, Rx Only, Farmakeio 1736 N Greenville Ave Richardson, TX 75081 | FDA | — | 2022-04-05 |
| REGULATORY | regulatory | D-1223-2022 — PT-141 10mg/mL a) 1mL-vial, b) 2 mL-vial, Refrigerate, Tailor Made Compounding | FDA | — | 2022-03-07 |
| REGULATORY | regulatory | D-0130-2021 — PT-141, 10 MG/ML, 2 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | FDA | — | 2020-11-30 |
| REGULATORY | regulatory | VYLEESI — FDA application NDA210557 | FDA | — | 2019-06-21 |
| REGULATORY | regulatory | D-0458-2019 — Bremelanotide (PT 141), 20mg injection, Rx Only, Promise Pharmacy Compounding Specialists 31818 US Hwy 19N, Palm Harbor, FL 34684 | FDA | — | 2018-12-17 |
| ANIMAL | evidence | A biodegradable suction patch for sustainable transbuccal peptide delivery. | Bremelanotide | animal | 2025-08-10 |
| ANIMAL | evidence | Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. | Vyleesi | Sexual function & libido · animal | 2025-04-01 |
| ANIMAL | evidence | Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. | Vyleesi | animal | 2020-07-15 |
| ANIMAL | evidence | Pharmacological profiling of neuropeptides on rabbit vaginal wall and vaginal artery smooth muscle in vitro. | Bremelanotide | Gut barrier & GI healing · animal | 2008-09-01 |
| ANIMAL | evidence | Bremelanotide: an overview of preclinical CNS effects on female sexual function. | Bremelanotide | Sexual function & libido · animal | 2007-11-01 |
| ANIMAL | evidence | Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. | PT 141 | Sexual function & libido · animal | 2004-07-06 |
| ANIMAL | evidence | Salmonellae in gulls and other free-living birds in the Czech Republic. | PT 141 | animal | 1995-02-01 |
| PRECLINICAL | evidence | Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling. | Bremelanotide | — | 2026-07-22 |
| PRECLINICAL | evidence | Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer. | Bremelanotide | Sexual function & libido | 2026-07-01 |
| PRECLINICAL | evidence | Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors. | Bremelanotide | — | 2026-06-24 |
| PRECLINICAL | evidence | FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective. | Bremelanotide | — | 2026-05-01 |
| PRECLINICAL | evidence | Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men? | Bremelanotide | — | 2026-05-01 |
| PRECLINICAL | evidence | Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. | PT 141 | — | 2026-04-27 |
| PRECLINICAL | evidence | Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. | Bremelanotide | — | 2026-01-01 |
| PRECLINICAL | evidence | Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov. | Bremelanotide | — | 2026-01-01 |
| PRECLINICAL | evidence | Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options. | Bremelanotide | Sexual function & libido | 2026-01-01 |